Contents
Academy · Research Writing · Regulatory writing · ICH guidelines
ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update
ICH guidelines allow a single dossier to satisfy regulators in multiple regions, rather than requiring a sponsor to demonstrate the same evidence separately to the FDA, the EMA and Japan’s PMDA under three different sets of rules.
The International Council for Harmonisation (ICH) guidelines sort into four categories, and the most consequential recent change to any of them — the Good Clinical Practice update, E6(R3) — reached final adoption in January 2025.
The four categories
The four ICH categories, with real examples
| Category | Covers | Example guidelines |
|---|---|---|
| Quality (Q) | Pharmaceutical development, manufacturing, stability | Q1 (stability testing), Q7 (GMP for active pharmaceutical ingredients) |
| Safety (S) | Nonclinical testing in vitro and in animals | Carcinogenicity, genotoxicity, reproductive toxicity studies |
| Efficacy (E) | Design, conduct, safety reporting and analysis of human clinical trials | E6 (Good Clinical Practice), E9 (statistical principles), E3 (clinical study reports) |
| Multidisciplinary (M) | Cross-cutting topics outside Q/S/E | M4 (Common Technical Document submission format) |
What changed in E6(R3), the current Good Clinical Practice guideline
ICH Regulatory Members endorsed the E6(R3) Step 4 text on 6 January 2025, and the European Medicines Agency adopted the Principles and Annex 1 on 12 December 2024 (Annex 2 follows on a later timeline, 25 June 2026). The revision restructures the guideline into Principles plus separate Annexes, moves toward a risk-based, proportionate approach to trial quality rather than a uniform checklist applied regardless of a trial’s actual risk profile, and is written to be media-neutral so it can accommodate digital health technologies and real-world data sources that the 2016 version did not anticipate.
Why ICH Harmonisation Matters
Before ICH, a sponsor developing a drug for multiple major markets effectively had to satisfy separate, differently structured requirements from each regulator covering the same underlying science. ICH guidelines, once adopted by a region’s regulator (FDA and EMA among them), let a single body of evidence and a single submission format — M4, the Common Technical Document — serve as the basis for that region’s review, rather than requiring the dossier to be rebuilt from scratch per region.
Frequently Asked Questions
Only once a region’s own regulator formally adopts them — ICH itself is a harmonisation body, not a regulatory authority. The FDA and EMA have adopted the core guidelines, which is why they function as a de facto global standard in practice.
Adoption and effective dates vary by region and by which Annex is involved — Annex 1 and Annex 2 of E6(R3) have different adoption timelines even within the EMA’s own schedule. Check the specific regulator’s current guidance before assuming either version applies to a given submission.
References and sources
- European Medicines Agency / ICH. "ICH E6(R3) Guideline for Good Clinical Practice." read 8 October 2026. Step 5, EMA adoption 12 Dec 2024 (Principles/Annex 1)
Each source carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 8). ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update. Pubrica. https://pubrica.com/ich-guidelines-pharmaceutical-regulations/
Pubrica Academy. “ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update.” Pubrica, 8 Oct. 2026, pubrica.com/ich-guidelines-pharmaceutical-regulations/.
Pubrica Academy (2026) ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update. Pubrica. Available at: https://pubrica.com/ich-guidelines-pharmaceutical-regulations/ (Accessed: 15 October 2026).
Pubrica Academy. “ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update.” Pubrica. October 8, 2026. https://pubrica.com/ich-guidelines-pharmaceutical-regulations/
Pubrica Academy, ‘ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update’ (Pubrica, 8 October 2026) <https://pubrica.com/ich-guidelines-pharmaceutical-regulations/> accessed 15 October 2026.
Pubrica Academy. ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update. [Internet]. Pubrica; 2026 Oct 8 [cited 2026 Oct 15]. Available from: https://pubrica.com/ich-guidelines-pharmaceutical-regulations/
Pubrica Academy, “ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update,” Pubrica, Oct. 8, 2026. [Online]. Available: https://pubrica.com/ich-guidelines-pharmaceutical-regulations/
@misc{ich_guidelines_pharmaceutical_regulati_2026,
author = {{Pubrica Academy}},
title = {ICH Guidelines: The Four Categories, and What Changed in the 2025 GCP Update},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/ich-guidelines-pharmaceutical-regulations/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.
How Pubrica helps
Pubrica tracks which ICH guideline version currently applies in each target region and writes regulatory documents against the version that is actually in force, not the one most recently announced.